Asosiy kontentga oʻtish
Maqola

Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

Boris BikbovIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyCaroline PurcellIstituti di Ricovero e Cura a Carattere ScientificoAndrew S. LeveyInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USAMari SmithIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyAmir AbdoliInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USAMolla AbebeIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyOladimeji AdebayoInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USAMohsen AfaridehInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USASanjay Kumar AgarwalInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USAMarcela Agudelo‐BoteroIstituti di Ricovero e Cura a Carattere ScientificoElham AhmadianIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyZiyad Al‐AlyInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USAVahid AlipourInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USAAmir Almasi‐HashianiInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USARajaa Al‐RaddadiInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USANelson Alvis‐GuzmánInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USASaeed AminiInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USATudorel AndreiInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USACătălina Liliana AndreiIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyZewudu AndualemIstituti di Ricovero e Cura a Carattere ScientificoMina AnjomshoaIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyJalal ArablooInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USAAlebachew Fasil AshagreIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyDaniel AsmelashInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USAZerihun AtaroIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyMaha AtoutInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USAMartin Amogre AyanoreIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyAlaa BadawiIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyAhad BakhtiariIstituti di Ricovero e Cura a Carattere ScientificoShoshana H. BallewInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USAAbbas BalouchiInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USAMaciej BanachIstituti di Ricovero e Cura a Carattere ScientificoSı́món BarqueraIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalySanjay BasuIstituti di Ricovero e Cura a Carattere ScientificoMulat Tirfie BayihInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USANeeraj BediInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USAAminu K. BelloInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USAIsabela M. BenseñorIstituti di Ricovero e Cura a Carattere ScientificoAli BijaniIstituti di Ricovero e Cura a Carattere ScientificoArchith BoloorIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyAntonio Maria BorzìLuis Alberto CámeraIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyJuan Jesús CarreroInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USAFélix CarvalhoIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyFranz CastroInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USAFerrán Catalá-LópezInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USAAlex R. ChangIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyKen Lee ChinIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalySheng‐Chia ChungInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USAMassimo CírilloInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USAEwerton CousinIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyLalit DandonaIstituti di Ricovero e Cura a Carattere ScientificoRakhi DandonaIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyAhmad DaryaniIstituti di Ricovero e Cura a Carattere ScientificoRajat Das GuptaFeleke Mekonnen DemekeIstituti di Ricovero e Cura a Carattere ScientificoGebre Teklemariam DemozIstituti di Ricovero e Cura a Carattere ScientificoDesilu Mahari DestaIstituti di Ricovero e Cura a Carattere ScientificoHuyen PhucIstituti di Ricovero e Cura a Carattere ScientificoBruce Bartholow DuncanInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USAAziz EftekhariInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USAAlireza EsteghamatiInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USASyeda Sadia FatimaIstituti di Ricovero e Cura a Carattere ScientificoJoão Carlos FernandesIstituti di Ricovero e Cura a Carattere ScientificoEduarda FernandesIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyFlorian FischerIstituti di Ricovero e Cura a Carattere ScientificoMarisa FreitasIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyMohamed M. GadGebreamlak Gebremedhn GebremeskelBegashaw Melaku GebresillassieIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyBirhanu GetaIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyMansour GhafourifardIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyAlireza GhajarIstituti di Ricovero e Cura a Carattere ScientificoNermin GhithIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyParamjit GillIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyIbrahim GinawiInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USARajeev GuptaIstituti di Ricovero e Cura a Carattere ScientificoNima Hafezi‐NejadIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyArvin Haj‐MirzaianInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USAArya Haj‐MirzaianIstituti di Ricovero e Cura a Carattere ScientificoNinuk HariyaniInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USAMehedi HasanInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USAMilad HasankhaniIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyAmir HasanzadehIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyHamid Yimam HassenIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalySimon I HayIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyBehnam HeidariInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USAClaudiu HerţeliuInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USAChi Linh HoangInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USAMostafa HosseiniIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo 24020, ItalyMihaela HostiucInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USASeyed Sina Naghibi IrvaniInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USASheikh Mohammed Shariful IslamIstituti di Ricovero e Cura a Carattere ScientificoNader Jafari BalalamiSpencer L JamesIstituti di Ricovero e Cura a Carattere ScientificoSimerjot K JassalIstituti di Ricovero e Cura a Carattere ScientificoVivekanand JhaInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USAJost B JonasIstituti di Ricovero e Cura a Carattere ScientificoFarahnaz JoukarIstituti di Ricovero e Cura a Carattere ScientificoJacek Jerzy JozwiakInstitute for Health Metrics and Evaluation, Seattle, WA 98121, USA
2020en
ABI

Annotatsiya

BACKGROUND: Health system planning requires careful assessment of chronic kidney disease (CKD) epidemiology, but data for morbidity and mortality of this disease are scarce or non-existent in many countries. We estimated the global, regional, and national burden of CKD, as well as the burden of cardiovascular disease and gout attributable to impaired kidney function, for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. We use the term CKD to refer to the morbidity and mortality that can be directly attributed to all stages of CKD, and we use the term impaired kidney function to refer to the additional risk of CKD from cardiovascular disease and gout. METHODS: The main data sources we used were published literature, vital registration systems, end-stage kidney disease registries, and household surveys. Estimates of CKD burden were produced using a Cause of Death Ensemble model and a Bayesian meta-regression analytical tool, and included incidence, prevalence, years lived with disability, mortality, years of life lost, and disability-adjusted life-years (DALYs). A comparative risk assessment approach was used to estimate the proportion of cardiovascular diseases and gout burden attributable to impaired kidney function. FINDINGS: Globally, in 2017, 1·2 million (95% uncertainty interval [UI] 1·2 to 1·3) people died from CKD. The global all-age mortality rate from CKD increased 41·5% (95% UI 35·2 to 46·5) between 1990 and 2017, although there was no significant change in the age-standardised mortality rate (2·8%, -1·5 to 6·3). In 2017, 697·5 million (95% UI 649·2 to 752·0) cases of all-stage CKD were recorded, for a global prevalence of 9·1% (8·5 to 9·8). The global all-age prevalence of CKD increased 29·3% (95% UI 26·4 to 32·6) since 1990, whereas the age-standardised prevalence remained stable (1·2%, -1·1 to 3·5). CKD resulted in 35·8 million (95% UI 33·7 to 38·0) DALYs in 2017, with diabetic nephropathy accounting for almost a third of DALYs. Most of the burden of CKD was concentrated in the three lowest quintiles of Socio-demographic Index (SDI). In several regions, particularly Oceania, sub-Saharan Africa, and Latin America, the burden of CKD was much higher than expected for the level of development, whereas the disease burden in western, eastern, and central sub-Saharan Africa, east Asia, south Asia, central and eastern Europe, Australasia, and western Europe was lower than expected. 1·4 million (95% UI 1·2 to 1·6) cardiovascular disease-related deaths and 25·3 million (22·2 to 28·9) cardiovascular disease DALYs were attributable to impaired kidney function. INTERPRETATION: Kidney disease has a major effect on global health, both as a direct cause of global morbidity and mortality and as an important risk factor for cardiovascular disease. CKD is largely preventable and treatable and deserves greater attention in global health policy decision making, particularly in locations with low and middle SDI. FUNDING: Bill & Melinda Gates Foundation.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

7 ta iqtibos0 ta foydalanilgan manba